Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

被引：6

作者：

Aftimos, P. G. ^{[1
]}

Cortes, J. ^{[2
]}

Bidard, F. C. ^{[3
]}

Kaklamani, V. ^{[4
]}

Bardia, A. ^{[5
]}

Neven, P. ^{[6
]}

Streich, G. ^{[7
,8
]}

Montero, A.

Forget, F. ^{[9
]}

Reynier, M. A. Mouret ^{[10
]}

Sohn, J. ^{[11
]}

Taylor, D. ^{[12
]}

Harnden, K. ^{[13
]}

Khong, H. ^{[14
]}

Kocsis, J. ^{[15
]}

Dalenc, F. ^{[16
]}

Dillon, P. ^{[17
]}

Tonini, G. ^{[18
]}

Grzegorzewski, K. J. ^{[19
]}

Lu, J. ^{[20
]}

机构：

[1] Inst Jules Bordet, Clin Trials Conduct Unit, Brussels, Belgium

[2] Int Breast Canc Ctr IBCC, Quiron Grp, Med Oncol, Barcelona, Spain

[3] Inst Curie, Med Oncol Dept, Paris, France

[4] UTHSCSA Univ Texas Hlth Sci Ctr San Antonio, 303 Regent Circle, San Antonio, TX USA

[5] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Haematol Oncol, Boston, MA USA

[6] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Dept Gynaecol Oncol, Campus Gasthuisberg, Leuven, Belgium

[7] Hosp Mil Cent Cirujano Mayor Dr Cosme Argerich, Buenos Aires, Argentina

[8] Case Western Reserve Univ, Med Oncol, Cleveland, OH USA

[9] Ctr Hosp Ardenne, Med Oncol, Libramont, Belgium

[10] Jean Perrin Ctr, Med Oncol, Clermont Ferrand, France

[11] Yonsei Univ, Med Oncol Dept, Seoul, South Korea

[12] CHU UCL Namur Site St Elisabeth, Dept Oncol, Namur, Belgium

[13] Inova Schar Canc Inst, Med Oncol, Fairfax, VA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Med Oncol, Magnolia Campus, Tampa, FL USA

[15] Bacs Kiskun Cty Teaching Hosp Kecskemet, Oncol Dept, Kecskemet, Hungary

[16] Ctr Claudius Regaud, Clin Res, Toulouse, France

[17] UVA Univ Virginia, Med Oncol, Sch Med, Div Hematol & Oncol, Charlottesville, VA USA

[18] Menarini Silicon Biosyst Inc, North Amer Operat, Med Oncol, Huntingdon Valley, PA USA

[19] Stemline Therapeut Inc, Clin Dev, New York, NY USA

[20] USC Univ Southern Calif, Med Dept, Norris Comprehens Canc Ctr, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.259

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

220P

引用

页码：S638 / S638

页数：1

共 50 条

[1] Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).
Kaklamani, Virginia G.
Bardia, Aditya
Aftimos, Philippe Georges
Cortes, Javier
Lu, Janice M.
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joohyuk
Taylor, Donatienne
Harnden, Kathleen Kiernan
Khong, Hung T.
Kocsis, Judit
Dalenc, Florence
Dillon, Patrick Michael
Tonini, Giulia
Grzegorzewski, Kris
Bidard, Francois-Clement
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Bardia, Aditya
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joo Hyuk
Vuylsteke, Peter
Harnden, Kathleen K.
Khong, Hung
Kocsis, Judit
Dalenc, Florence
Kaklamani, Virginia
Dillon, Patrick
Babu, Sunil
Waters, Simon
Deleu, Ines
Garcia-Saenz, Jose
Bria, Emilio
Cazzaniga, Marina
Lu, Janice
Aftimos, Philippe
Cortes, Javier
Liu, Shubin
Laurent, Dirk
Conlan, Maureen G.
Bidard, Francois-Clement
CANCER RESEARCH, 2022, 82 (04)
[3] Elacestrant vs standard-of-care in ER+/HER2-advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Bardia, Aditya
O'Shaughnessy, Joyce
Bidard, Francois-Clement
Neven, Patrick
Garcia-Saenz, Jose Angel
Aftimos, Philippe
Cortes, Javier
Lu, Janice
Tonini, Giulia
Theall, Kathy Puvana
Paoli, Alessandro
Kaklamani, Virginia
CANCER RESEARCH, 2024, 84 (09)
[4] Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
[5] EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
Bardia, A.
Lu, J.
Kaklamani, V.
Jung, J.
Anderson-Villaluz, A. T.
Conlan, M. G.
Bidard, F-C.
Cortes, J.
Aftimos, P. G.
ANNALS OF ONCOLOGY, 2020, 31 : S80 - S80
[6] EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
Aftimos, Philippe
Bardia, Aditya
Kaklamani, Virginia G.
Lu, Janice
Bihani, Teeru
Jung, JungAh
Anderson-Villaluz, Alfred T.
Conlan, Maureen G.
Cortes, Javier
CANCER RESEARCH, 2020, 80 (04)
[7] Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer
Bihani, Teeru
Jung, JungAh
Patel, Hitisha K.
Bardia, Aditya
Kabos, Peter
Kaklamani, Virginia
Jager, Agnes
Aftimos, Philippe
Wilks, Sharon
de Vries, Elisabeth
Harb, Wael
Richards, Donald
Weise, Amy
Wesolowski, Robert
van Oordt, Catharina C. W. Menke-van der Houven
Conkling, Paul
Neven, Patrick
Conlan, Maureen G.
CANCER RESEARCH, 2020, 80 (04)
[8] Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)
Kaklamani, Virginia G.
Bidard, Francois Clement
Neven, Patrick
Montero, Alberto J.
Mouret-Reynier, Marie-Ange
Sohn, Joohyuk
Taylor, Donatienne
Forget, Frederic
Harnden, Kathleen Kiernan
Khong, Hung T.
Kocsis, Judit
Dalenc, Florence
Dillon, Patrick Michael
Waters, Simon
Garcia-Saenz, Jose A.
Aftimos, Philippe Georges
Cortes, Javier
Scartoni, Simona
Habboubi, Nassir
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard, Francois-Clement
Kaklamani, Virginia G.
Neven, Patrick
Streich, Guillermo
Montero, Alberto J.
Forget, Frederic
Mouret-Reynier, Marie-Ange
Sohn, Joo Hyuk
Taylor, Donatienne
Harnden, Kathleen K.
Khong, Hung
Kocsis, Judit
Dalenc, Florence
Dillon, Patrick M.
Babu, Sunil
Waters, Simon
Deleu, Ines
Saenz, Jose A. Garcia
Bria, Emilio
Cazzaniga, Marina
Lu, Janice
Aftimos, Philippe
Cortes, Javier
Liu, Shubin
Tonini, Giulia
Laurent, Dirk
Habboubi, Nassir
Conlan, Maureen G.
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3246 - +
[10] SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
Chandarlapaty, S.
Bardia, A.
Lord, S.
Linden, H.
Pelekanou, V.
Ternes, N.
Ming, J.
Boutet, V.
Boitier, E.
Gosselin, A.
Lee, J. Sang
Bele, W. Dos-Santos
Protopopov, A.
Celanovic, M.
Bauchet, A-L.
Campone, M.
ANNALS OF ONCOLOGY, 2020, 31 : S351 - S351

← 1 2 3 4 5 →